Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2227 : JMSU1  update : 2022/09/07
CommentHuman cell line derived from urinary bladder carcinoma. Derived from ascites.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Morita, Tasuo
Originator Morita, Tatsuo
Year of deposit 2002
Another name HMSU-1
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 75 years
Tissue bladder, ascites meta
Disease name urinary bladder carcinoma
Metastastatic ability Yes
Metastatsd tissue lung, liver, bone marrow, lympho node, peritoneum
Classification cancer
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_2081
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 0
User's Publication 1


To topTop
Reference

To topTop
User's Publication
14224  Aya Kikuchi, Tomoyuki Suzuki, Taisuke Nakazawa, Masateru Iizuka, Ayako Nakayama, Tohru Ozawa, Minoru Kameda, Nobuaki Shindoh, Tadashi Terasaka, Masaaki Hirano, Sadao Kuromitsu  ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance  Cancer Science  2017  108:236-242 



Back Back Return Top Page